HO Launch Gains Traction, but Valuation Leaves Little Room for Error

What happened

Rhythm Pharmaceuticals reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, marking a 19% sequential increase driven by early traction in the acquired hypothalamic obesity (HO) launch. Management highlighted a positive reception to the U.S. HO introduction, with early patient starts and payer coverage building as expected. The revenue uptick aligns with the base-case assumption that HO will drive growth, though operating losses persist and cash runway remains reliant on external capital. Shares trading near $105 continue to embed a smooth multi-indication expansion with little margin for error. The quarter confirms that HO is contributing, but valuation remains extended relative to current fundamentals.

Implication

The 19% sequential sales growth demonstrates that the HO label expansion is converting into real demand, validating a key pillar of the investment thesis. However, Rhythm still burns cash and faces dilution risk, while the shares already price in much of the near-term commercial uplift. Investors should monitor whether SG&A growth decelerates relative to revenue, signaling operating leverage. A pullback toward the $80 area would offer a more attractive risk/reward, but chasing at current levels carries downside if HO momentum stalls or later-stage trials disappoint. We maintain a WAIT stance, favoring accumulation on weakness rather than at today's elevated multiple.

Thesis delta

The HO launch is progressing in line with expectations, reinforcing confidence in the core growth driver. However, with the stock near our $110 base-case implied value and profitability still years away, the risk/reward remains balanced. No rating change is warranted, but positive HO data modestly de-risks the launch assumption.